Recent News

• 08.22.2025 - Aptose Biosciences Announces Results of Reconvened Annual and Special Shareholders Meeting and Appointment of Ernst & Young LLP as New Auditor
• 08.22.2025 - Aptose Biosciences Announces Results of Reconvened Annual and Special Shareholders Meeting and Appointment of Ernst & Young LLP as New Auditor
• 08.18.2025 - Aptose Reports Early Data Demonstrating Tuspetinib Improves Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML in Phase 1/2 TUSCANY Trial
• 08.18.2025 - Aptose Reports Early Data Demonstrating Tuspetinib Improves Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML in Phase 1/2 TUSCANY Trial
• 08.13.2025 - Aptose Reports Second Quarter 2025 Results
• 08.13.2025 - Aptose Reports Second Quarter 2025 Results
• 08.06.2025 - Aptose Enrollment is Open for 160 mg Dosing Cohort of Tuspetinib in Phase 1/2 TUSCANY Trial of Frontline Triple Drug Therapy
• 08.06.2025 - Aptose Enrollment is Open for 160 mg Dosing Cohort of Tuspetinib in Phase 1/2 TUSCANY Trial of Frontline Triple Drug Therapy
• 08.01.2025 - Aptose Selects Ernst & Young Global Limited as its New Independent Auditor and Calls Reconvened Meeting of its Shareholders
• 08.01.2025 - Aptose Selects Ernst & Young Global Limited as its New Independent Auditor and Calls Reconvened Meeting of its Shareholders

Recent Filings

• 08.22.2025 - 8-K Current report
• 08.22.2025 - EX-99.1 EX-99.1
• 08.18.2025 - EX-99.1 EX-99.1
• 08.18.2025 - 8-K Current report
• 08.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.13.2025 - 8-K Current report
• 08.13.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.13.2025 - EX-99.1 EX-99.1
• 08.06.2025 - 8-K Current report
• 08.06.2025 - EX-99.1 EX-99.1